Company profilePharmaceutical#44 of 1,318 in Pakistan6 DRAP alerts

Pfizer Laboratories (Pvt) Ltd.

Pharmaceutical company · 254 brands · 276 molecules

Ranked #4 of 44 companies in Antineoplastics

254 registered products 96 pharmaceutical brands 276 distinct molecules 6 DRAP alerts

Company overview

254

registered products

pharmaceutical brands

276

distinct molecules

therapeutic classes

DRAP alerts

Pfizer Laboratories (Pvt) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 254 product registrations across 276 distinct molecules. It is the 44th largest registrant in Pakistan by product count, and ranks 4th of 44 in Antineoplastics. Its portfolio is concentrated in Antineoplastics and Anti-Infectives. DRAP has issued 6 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Pfizer

188 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Cancer 12

Adriblastina10mg/mlceiling Rs 1,051.85 Adriblastina50mgRs 2,394.39 Adriblastina10mgRs 700.79 Carpsol10mgceiling Rs 1,672.1 Carpsol150mgRs 2,306.64 Cisplasol1mgceiling Rs 2,379.57 Cisplasol10mgceiling Rs 2,379.57 Cisplasol50mgRs 1,326.57 Cytosar100mgRs 180.03 Cytosar500mgRs 867.15 Farmorubicin50mgRs 3,635.42 Farmorubicin10mgRs 788.39

Pain Management 9

Arthrotec50mg 200mcgRs 301.2 Arthrotec50mgRs 301.2 Feldene0.5% 25gRs 494.09 Feldene10mgRs 123.7 Feldene20mgRs 832.8 Feldene10mgRs 123.7 Feldene20mgRs 832.8 Feldene25gRs 494.09 FeldenetopicalRs 233.15

Anti-Infectives 7

Combantrin250mgRs 1,026 CombantrinRs 1,026 Dalacin C150mgRs 351.52 Dalacin C300mg/2mlRs 213.27 Dalacin C300mgRs 647.36 Dalacinc600mgRs 265.24 Diflucaninf2mgRs 560

Hormone Regulators 6

Deltacortril Ec5MgRs 432 DeltacortrilecRs 455.1 Depo Provera150mg/mlceiling Rs 7,418.46 Depomedrol40mgRs 182.3 Depomedrol80mgRs 263.01 Depoprovera150mgRs 65

Cardiac Care 5

Caduet10mgRs 490 Cardura2MgRs 378.3 Cardura4MgRs 1,490.8 Dilzem60mgRs 237 Dilzem30mgRs 130.5

Antineoplastics 4

Campto40mg/mlceiling Rs 10,959.73 Campto100mg/5mlceiling Rs 26,303.37 Campto40mgceiling Rs 10,959.73 Campto100mgceiling Rs 26,303.37

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

ceilings with an approval date

not revised in 2+ years

2024

oldest approval year

202439

20253

202630

Longest without revision

Xalacom Eye 2.5MlRs 2,246.34 · approved 01 Jul, 2024 Dalacin C 150mgRs 347.69 · approved 01 Jul, 2024 Dalacin C 300mgRs 398.04 · approved 01 Jul, 2024 Dalacin T 30mlRs 322.99 · approved 01 Jul, 2024 SOLU-CORTEF 100 MGRs 234.75 · approved 01 Jul, 2024 Dilantin 100mgRs 239.68 · approved 01 Jul, 2024

Top molecules by brand count

Ascorbic Acid11 brands

Thiamine10 brands

Pyridoxine10 brands

Cyanocobalamin10 brands

Riboflavin10 brands

Nicotinamide9 brands

Clindamycin8 brands

Magnesium Oxides And Hydroxides7 brands

Retinol6 brands

Ethambutol5 brands

Therapeutic classes

Conditions treated

Price band (DRAP official ceilings)

Registered products priced by source

DRAP-official77 products · Rs 43.58 – Rs 127,815.44

DVAGO55 products · Rs 27.8 – Rs 8,878.65

Servaid91 products · Rs 20 – Rs 4,210.65

Median across source: Rs 490

Regulatory record

6 alerts in the DRAP feed we track.

Drug Safety Alert: Risk of serious heart-related events, blood clots, cancer and death wit

2023-04-13

Recall Alert: Drug Product; Ponstan Forte 500mg Tablets (Batch # 2050533) by M/s Pfizer Pa

2022-11-30

Rapid Alert: Drug Product; Falsified Xanax 0.5mg Tablets identified in the market

2022-11-29

Voluntary Recall Alert: Drug Product; Meronem 1g Injection (Batch #4A20B27 and Batch # 4A2

2022-06-02

Drug Product Recall: M/S. Pfizer Pakistan Limited, Karachi issues nation wide voluntary re

2022-02-08

Drug Product Recall: Meronem Injection (Batch # 4B20E273) by M/s Pfizer Pakistan Limited,

2021-08-02

Competitive set

Companies whose registered portfolio overlaps most with this one.

Atco Pharma International (Pvt) Ltd73 shared molecules

Wilshire Laboratories (Private) Limited66 shared molecules

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.65 shared molecules

HELIX PHARMA (PRIVATE) LIMITED63 shared molecules

ENGLISH PHARMACEUTICALS INDUSTRIES58 shared molecules

CCL Pharmaceuticals (Pvt.) Ltd. DML: 00005254 shared molecules

NEUTRO PHARMA (PVT) LTD.52 shared molecules

Albro Pharmaceuticals51 shared molecules

ABBOTT LABORATORIES (PAKISTAN) LIMITED.51 shared molecules

BIO LABS (PVT) LTD.50 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Atco Pharma International (Pvt) Ltd holds 200 molecules not in this portfolio

Wilshire Laboratories (Private) Limited holds 113 molecules not in this portfolio

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 129 molecules not in this portfolio

Get the full profile for Pfizer

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included